Heat shock preconditioning mesenchymal stem cells attenuate acute lung injury via reducing NLRP3 inflammasome activation in macrophages.
Acute lung injury
Heat shock
Macrophage
NLRP3 inflammasome
Umbilical cord-derived mesenchymal stem cells
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
17 05 2021
17 05 2021
Historique:
received:
01
01
2021
accepted:
07
04
2021
entrez:
18
5
2021
pubmed:
19
5
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Acute lung injury (ALI) remains a common cause of morbidity and mortality worldwide, and to date, there is no effective treatment for ALI. Previous studies have revealed that topical administration of mesenchymal stem cells (MSCs) can attenuate the pathological changes in experimental acute lung injury. Heat shock (HS) pretreatment has been identified as a method to enhance the survival and function of cells. The present study aimed to assess whether HS-pretreated MSCs could enhance immunomodulation and recovery from ALI. HS pretreatment was performed at 42 °C for 1 h, and changes in biological characteristics and secretion functions were detected. In an in vivo mouse model of ALI, we intranasally administered pretreated umbilical cord-derived MSCs (UC-MSCs), confirmed their therapeutic effects, and detected the phenotypes of the macrophages in bronchoalveolar lavage fluid (BALF). To elucidate the underlying mechanisms, we cocultured pretreated UC-MSCs with macrophages in vitro, and the expression levels of inflammasome-related proteins in the macrophages were assessed. The data showed that UC-MSCs did not exhibit significant changes in viability or biological characteristics after HS pretreatment. The administration of HS-pretreated UC-MSCs to the ALI model improved the pathological changes and lung damage-related indexes, reduced the proinflammatory cytokine levels, and modulated the M1/M2 macrophage balance. Mechanistically, both the in vivo and in vitro studies demonstrated that HS pretreatment enhanced the protein level of HSP70 in UC-MSCs, which negatively modulated NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in alveolar macrophages. These effects were partially reversed by knocking down HSP70 expression. HS pretreatment can enhance the beneficial effects of UC-MSCs in inhibiting NLRP3 inflammasome activation in macrophages during ALI. The mechanism may be related to the upregulated expression of HSP70.
Identifiants
pubmed: 34001255
doi: 10.1186/s13287-021-02328-3
pii: 10.1186/s13287-021-02328-3
pmc: PMC8127288
doi:
Substances chimiques
Inflammasomes
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Nlrp3 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
290Références
N Engl J Med. ;377(19):1904
pubmed: 29120142
Am J Respir Cell Mol Biol. 2011 May;44(5):725-38
pubmed: 21531958
Am J Respir Cell Mol Biol. 2021 May;64(5):547-556
pubmed: 33332993
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
J Immunol Res. 2018 Dec 3;2018:7283703
pubmed: 30622980
Curr Opin Crit Care. 2016 Feb;22(1):1-6
pubmed: 26645551
Lancet Respir Med. 2018 Sep;6(9):651-653
pubmed: 30078619
Cytotherapy. 2015 Apr;17(4):359-68
pubmed: 25536863
J Immunol. 2010 Nov 15;185(10):5743-50
pubmed: 20926795
Vet Q. 1981 Jan;3(1):34-7
pubmed: 6259771
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Stem Cell Res Ther. 2020 Jan 3;11(1):2
pubmed: 31900217
Stem Cells. 2014 Jun;32(6):1553-63
pubmed: 24307525
Stem Cell Res Ther. 2018 Sep 26;9(1):240
pubmed: 30257708
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16513-16518
pubmed: 31363052
Stem Cells. 2011 Jun;29(6):913-9
pubmed: 21506195
Cell Death Dis. 2020 Aug 19;11(8):657
pubmed: 32814765
Cells. 2019 Dec 19;9(1):
pubmed: 31861724
Biores Open Access. 2014 Aug 1;3(4):137-49
pubmed: 25126478
Hepatology. 2016 Nov;64(5):1683-1698
pubmed: 27474884
Stem Cell Res Ther. 2021 Jan 7;12(1):15
pubmed: 33413632
Int J Mol Sci. 2019 May 05;20(9):
pubmed: 31060326
Int J Mol Med. 2018 May;41(5):2527-2534
pubmed: 29532861
Cell Death Dis. 2016 Dec 22;7(12):e2524
pubmed: 28005072
Stem Cell Res Ther. 2017 Jun 8;8(1):140
pubmed: 28595619
J Biol Chem. 2015 Jan 23;290(4):1994-2006
pubmed: 25492872
Am J Transl Res. 2016 May 15;8(5):2033-46
pubmed: 27347312
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8151-E8158
pubmed: 27911817
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
Science. 2017 May 5;356(6337):513-519
pubmed: 28473584
Stem Cells. 2018 Apr;36(4):602-615
pubmed: 29341339
J Surg Res. 2012 Dec;178(2):935-48
pubmed: 22658855
World J Gastroenterol. 2015 Dec 7;21(45):12822-34
pubmed: 26668506
JAMA. 2018 Jul 17;320(3):305
pubmed: 30027240
Cytotherapy. 2014 May;16(5):579-85
pubmed: 24113425
Biochem Biophys Res Commun. 2018 Apr 15;498(4):988-995
pubmed: 29550474
EBioMedicine. 2018 Oct;36:140-150
pubmed: 30197023
FASEB J. 2020 Jan;34(1):1516-1531
pubmed: 31914698
Cell Biochem Biophys. 2015 Jan;71(1):481-9
pubmed: 25287672
Stem Cell Res Ther. 2019 Feb 13;10(1):56
pubmed: 30760307
Blood. 2003 Sep 15;102(6):2115-21
pubmed: 12805066
Crit Care Med. 2016 Jul;44(7):e553-62
pubmed: 26963321
Sci Rep. 2016 May 19;6:26162
pubmed: 27194621
World J Hepatol. 2018 Jan 27;10(1):1-7
pubmed: 29399273
Crit Care. 2018 Dec 20;22(1):353
pubmed: 30572913
Stem Cell Reports. 2017 Oct 10;9(4):1109-1123
pubmed: 28966116
Cells. 2019 Aug 20;8(8):
pubmed: 31434287
PLoS Med. 2007 Sep;4(9):e269
pubmed: 17803352
J Pineal Res. 2016 May;60(4):405-14
pubmed: 26888116
Stem Cell Res Ther. 2019 Nov 26;10(1):348
pubmed: 31771642
Free Radic Biol Med. 2014 Nov;76:114-26
pubmed: 25106704
Ann Transl Med. 2020 Mar;8(6):334
pubmed: 32355778
Nat Commun. 2018 Nov 16;9(1):4700
pubmed: 30446660
Cell Prolif. 2019 Mar;52(2):e12546
pubmed: 30537044
Stem Cells Transl Med. 2017 Mar;6(3):713-719
pubmed: 28297565
Am J Respir Cell Mol Biol. 2012 Oct;47(4):417-26
pubmed: 22721830
FASEB J. 2019 Feb;33(2):1695-1710
pubmed: 30226809
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1275-1286
pubmed: 28598224